Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 16/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19743985 | 0.85 | GPR35 (0.51) | GPR35KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL30225059 | 0.85 | MCHR1 (0.41) | GPR35KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL21175005 | 0.85 | GPR35 (0.50) | GPR35KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL27602177 | 0.84 | GPR35 (0.56) | GPR35KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL19744234 | 0.84 | GPR35 (0.68) | GPR35KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL19743740 | 0.80 | GPR35 (0.63) | GPR35KDM4EALDH1A1 | |
| SCHEMBL19744049 | 0.80 | GPR35 (0.59) | GPR35KDM4EALDH1A1 | |
| SCHEMBL6333455 | 0.80 | GPR35 (0.51) | GPR35KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL2895230 | 0.79 | PIM1 (0.45) | GPR35KDM4ECSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10915405 | 0.79 | GPR35 (0.61) | GPR35KDM4EUSP2CSNK2A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| CN-109641864-B | Anti-infective agents | 邓迪大学 | 2023-04-04 | — | — | CN | disclosed |
| US-11485720-B2 | Anti-infective agents | UNIVERSITY OF DUNDEE (GB) | 2022-11-01 | — | — | US | disclosed |
| EP-3472141-B1 | ANTI-INFECTIVE AGENTS | UNIV DUNDEE (GB) | 2022-10-05 | — | — | EP | disclosed |
| CN-114401952-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3962899-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20210101877-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2021-04-08 | — | — | US | disclosed |
| US-20210101877-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2021-04-08 | — | — | US | disclosed |
| WO-2020223536-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20190225592-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2019-07-25 | — | — | US | disclosed |
| US-20060276485-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2006-12-07 | — | — | US | disclosed |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2006-10-26 | — | — | US | disclosed |
| EP-1606278-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-21 | — | — | EP | disclosed |
| EP-1606281-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-21 | — | — | EP | disclosed |
| EP-1603912-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| EP-1603911-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004083199-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083198-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083209-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083208-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276485-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | GPR35 59/4885KDM4E 165/4885USP2 3419/4885 |
| US-11485720-B2 | Anti-infective agents | C1R, RRS1, ARG1 | GPR35 3114/4885KDM4E 2159/4885USP2 3354/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | GPR35 3535/4885KDM4E 4640/4885USP2 1932/4885 |
| US-20210101877-A1 | ANTI-INFECTIVE AGENTS | C1R, RRS1, ARG1 | GPR35 3114/4885KDM4E 2159/4885USP2 3354/4885 |
| US-20190225592-A1 | ANTI-INFECTIVE AGENTS | C1R, ARG1, MSR1 | GPR35 3007/4885KDM4E 2344/4885USP2 3242/4885 |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | GPR35 59/4885KDM4E 165/4885USP2 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.